Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by robertshawon Feb 24, 2018 11:19pm

108 Views

Post# 27616223

RE:RE:SPIE. Photonics Europe - April 2018

Bluebomber6 wrote:
Eoganacht wrote: Biophotonics: Photonic Solutions for Better Health Care

MONDAY 23 APRIL 2018

SESSION 1 MON 11:30 TO 12:40

Monte Carlo based light propagation models to improve efficacy of

biophotonics based therapeutics of hollow organs and solid tumours

including photodynamic therapy and photobiomodulation, Lothar D. Lilge,

Univ. Health Network (Canada); Jeffrey Cassidy, Abdul-Amir Yassine, William

Kingsford, Univ. of Toronto (Canada); Yiwen Xu, Brian C. Wilson, Univ. Health

Network (Canada); Vaughn Betz, Univ. of Toronto (Canada). . . . . . . . [10685-2]

SESSION 3 MON 16:05 TO 17:45

Personalizing cytotoxic dose for Ru(II) coordination complex mediated

photodynamic therapy in nonmuscle invasive bladder cancer (Invited

Paper), Lothar D. Lilge, Univ. Health Network (Canada); Arkadii Mandel,

Theralase, Inc. (Canada); Savo Lazic, Pavel Kaspler, Theralase, Inc. (Canada);

Girish Kulkarni, Michael Jewett, Univ. Health Network (Canada). . . . [10685-12]

An invited paper? Pavel Kaspler, THERALASE INC! Well, RW must be doing something right. A storm in a coffeecup, that is all the OSC is about, a slap on the wrist, lets get on to treating cancer patients with the most remarkable treatment available! Now that this silly issue wih fli is behind us, no more clouds, watch the news come from our CEO, and watch the market take notice. A good rain cleans everything away, bright sunshine ahead. You watch! Roger will make us proud.